Recombinant microorganisms comprising at least one exogenous nucleic acid sequence and capable of producing adipate semialdehyde are provided. Adipate semialdehyde may be produced in a synthesis pathway utilizing a single thiolase reaction. Adipate semialdehyde may also be produced from intermediates consisting of alpha, omega difunctional aliphatic organic molecules. Methods of using recombinant microorganisms to produce 6-aminocaproic acid, adipic acid, hexamethylenediamine and 1.6-hexanediol are also provided.

Recombinant microorganisms comprising at least one exogenous nucleic acid sequence and capable of producing adipate semialdehyde are provided. Adipate semialdehyde may be produced in a synthesis pathway utilizing a single thiolase reaction. Adipate semialdehyde may also be produced from intermediates consisting of alpha, omega difunctional aliphatic organic molecules. Methods of using recombinant microorganisms to produce 6-aminocaproic acid, adipic acid, hexamethylenediamine and 1.6-hexanediol are also provided.

A method for biosynthesis of polymer precursors, including, adipic acid, 1,6-hexanediol, 6-hydroxyhexanoic and 6-aminocaproic acids from carboxylic acids is provided. A method for biosynthesis of adipic acid from six-carbon dicarboxylic acids having α, β-enoate reductase activity by treatment with an enzyme is provided. The biocatalytic conversion of aliphatic and hydroxycarboxylic acids to corresponding aldehydes, alcohols, and amines using novel carboxylate reductases, aldehyde reductases, and aminotransferases is described. Also provided are genetically engineered microorganisms for use in the biosynthetic processes.

A method for biosynthesis of polymer precursors, including, adipic acid, 1,6-hexanediol, 6-hydroxyhexanoic and 6-aminocaproic acids from carboxylic acids is provided. A method for biosynthesis of adipic acid from six-carbon dicarboxylic acids having α, β-enoate reductase activity by treatment with an enzyme is provided. The biocatalytic conversion of aliphatic and hydroxycarboxylic acids to corresponding aldehydes, alcohols, and amines using novel carboxylate reductases, aldehyde reductases, and aminotransferases is described. Also provided are genetically engineered microorganisms for use in the biosynthetic processes.

This document describes biochemical pathways for producing adipic acid, caprolactam, 6-aminohexanoic acid, hexamethylenediamine or 1,6-hexanediol by forming two terminal functional groups, comprised of carboxyl, amine or hydroxyl groups, in a C6 aliphatic backbone substrate. These pathways, metabolic engineering and cultivation strategies described herein rely on CoA-dependent elongation enzymes or analogues enzymes associated with the carbon storage pathways from polyhydroxyalkanoate accumulating bacteria.

This document describes biochemical pathways for producing adipic acid, caprolactam, 6-aminohexanoic acid, hexamethylenediamine or 1,6-hexanediol by forming two terminal functional groups, comprised of carboxyl, amine or hydroxyl groups, in a C6 aliphatic backbone substrate. These pathways, metabolic engineering and cultivation strategies described herein rely on CoA-dependent elongation enzymes or analogues enzymes associated with the carbon storage pathways from polyhydroxyalkanoate accumulating bacteria.

Disclosed are biosynthetic methods and engineered microorganism that enhance or improve the biosynthesis of hexamethylenediamine, caproic acid or caprolactam. The engineered microorganisms include selected aldehyde dehydrogenase activity.

Disclosed are biosynthetic methods and engineered microorganism that enhance or improve the biosynthesis of hexamethylenediamine, caproic acid or caprolactam. The engineered microorganisms include selected aldehyde dehydrogenase activity.

Disclosed are a genetically modified microorganism with an ability to produce 3-hydroxyadipic acid, α-hydromuconic acid, and/or adipic acid in high yield, and a method of producing 3-hydroxyadipic acid, α-hydromuconic acid, and/or adipic acid by using the genetically modified microorganism. The genetically modified microorganism has an ability to produce 3-hydroxyadipic acid, α-hydromuconic acid, and/or adipic acid and is deficient in the function of pyruvate kinase, in which the activities of phosphoenolpyruvate carboxykinase and of an enzyme that catalyzes the reaction of reducing 3-oxoadipyl-CoA to 3-hydroxyadipyl-CoA are enhanced.

The invention provides a non-naturally occurring microbial organism having a 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid pathway. The microbial organism contains at least one exogenous nucleic acid encoding an enzyme in the respective 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid pathway. The invention additionally provides a method for producing 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid. The method can include culturing a 6-aminocaproic acid, caprolactam or hexametheylenediamine producing microbial organism, where the microbial organism expresses at least one exogenous nucleic acid encoding a 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid pathway enzyme in a sufficient amount to produce the respective product, under conditions and for a sufficient period of time to produce 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid.